IRCT20120703010178N19 IRCT 2020-02-07 Shahid Beheshti University of Medical Sciences Augmented renal clearance (ARC) and Meropenem concentration Evaluation of prevalence of Augmented renal clearance (ARC) and serum concentration of Meropenem with two different dosing regimens in critically ill patients 2019-06-22 anticipated 20 Complete https://irct.ir/trial/39416 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2-3 Augmented renal clearance (ARC). Intervention group: Patients with creatinine clearance of more than or equal to 130 ml/min, based on 12-hr urine collection, who receive meropenem (Ronakpharm, Iran) will be recruited in the study. Study subjects will receive meropenem, 1 g three times daily as 4-hr infusion. After 24 hours, at steady state, two blood samples, 1 hour after termination of infusion and 0.5 hour before next dose, will be gathered. Then the dose of meropenem will be increased to 2 g three times in day and again, after 24 hours, one hour after end of infusion and half an hour before receiving the next dose of meropenem the blood sample will be drawn. Meropenem concentration will be determined by HPLC method.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Patient privacy